Recombinant TNFSF13B (Tabalumab Biosimilar) antibody (AA 133-285)

Catalog No. ABIN7487690

This Rabbit Chimeric antibody specifically detects TNFSF13B (Tabalumab Biosimilar) in ELISA, WB, FACS, Func, IF, IP and Neut. It exhibits reactivity toward Human.

Quick Overview for Recombinant TNFSF13B (Tabalumab Biosimilar) antibody (AA 133-285) (ABIN7487690)

Target: TNFSF13B (Tabalumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Chimeric

Conjugate: This TNFSF13B (Tabalumab Biosimilar) antibody is un-conjugated

Application: ELISA, Western Blotting (WB), Flow Cytometry (FACS), Functional Studies (Func), Immunofluorescence (IF), Immunoprecipitation (IP), Neutralization (Neut)

Product Details anti-TNFSF13B (Tabalumab Biosimilar) Antibody

Binding Specificity: AA 133-285

Purpose: Anti-CD257 (BAFF) [Tabalumab], Rabbit IgG, kappa

Specificity: Tabalumab neutralises soluble and membrane-bound BAFF, inhibiting BAFF binding to BR3, TACI and BCMA.

Cross-Reactivity: Cynomolgus, Rabbit

Characteristics:

Original Species of Ab: Human

Original Format of Ab: IgG4

Purification: Protein A affinity purified

Immunogen: Monoclonal antibodies were generated by immunizing human immunoglobulin transgenic mice with soluble human BAFF (amino acids 133-285). Eight mice producing serum antibody titers to human BAFF were injected intravenously with 10 mug human BAFF in phosphate buffered saline. The spleen was harvested 3 days later from each mouse and fused with myeloma cells. 20 Hybridomas were tested for specific binding to human BAFF and to make sure they were expressing human immunoglobulin heavy and light chains by enzyme-linked immunosorbent assay (ELISA). The hybridoma producing the antibody that eventually became tabalumab was a human IgG1 isotype. The antibody was then engineered to a human IgG4 isotype for complete neutralization of BAFF without depletion of BAFF-expressing cells.

Isotype: IgG kappa

Application Details

Application Notes: Tabalumab has been tested in patients with systemic lupus erythematosus (Merrill 2015) and in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (Genovese 2013).

Comment:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for TNFSF13B (Tabalumab Biosimilar)

Target: TNFSF13B (Tabalumab Biosimilar)

Background: TNFSF20, B-cell activating factor, Tumor Necrosis Factor Superfamily Member 13b, BAFF, Tumor Necrosis Factor (Ligand) Superfamily, Member 13b, Dendritic Cell-Derived TNF-Like Molecule, TALL-1, TALL1, ZTNF4, BLYS, Tumor Necrosis Factor (Ligand) Superfamily, Member 20, Tumor Necrosis Factor Ligand Superfamily Member 13B, TNF- And APOL-Related Leukocyte Expressed Ligand 1, TNF And ApoL-Related Leukocyte Expressed Ligand 1, Tumor Necrosis Factor-Like Protein ZTNF4, TNF Homolog That Activates Apoptosis, Tumor Necrosis Factor Ligand 7A, ApoL Related Ligand TALL-1, B-Lymphocyte Stimulator, B Lymphocyte Stimulator, CD257 Antigen, Delta4 BAFF, Delta BAFF, TNLG7A, THANK, DTL, LY 2127399, LY2127399

UniProt: Q9Y275